drugset / Trial / NCT00247559

Botulinum Type A Toxin in the Treatment of Lateral Canthal Lines (Crow's Feet)

NCT00247559 ↗

Phase 2 Completed 221 enrolled Ipsen
RandomizedParallel-groupDouble-blindTreatment

Summary

Despite the wealth of information in the literature regarding the cosmetic applications of botulinum type A toxin (BoNT-A), and the widespread use of the BoNT-A for cosmetic applications, the number of randomised, controlled clinical trials is small. Much of the published information is based on open-label studies or anecdotal data. Of the robust trial data that is available, the vast majority relates to the treatment of glabellar lines, and there is little data available regarding the use of BoNT-A in lateral canthal lines. This study aims to determine the optimum dose for the use of BoNT-A in this area.

Timeline

Start
2004-05
Primary completion
2005-04-08
Completion
2005-04-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 15 iu —
Subject Botulinum toxin type A Protein / enzyme biologic 30 iu —
Subject Botulinum toxin type A Protein / enzyme biologic 45 iu —

Indications